Cell‐free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls.

Blanc‐Durand and colleagues present a prospective analysis of cell‐free DNA in patients with recurrent, advanced, or metastatic endometrial cancer, which offers insights into its potential application in molecular classification and the evolving targeted therapy landscape of this disease. More research is needed to validate cell‐free DNA's clinical utility but its potential to guide therapy and improve patient outcomes warrants ongoing exploration. [ABSTRACT FROM AUTHOR]